ARTELO BIOSCIENCES INC

ARTLNASDAQ

🏆 #4362 by market capEarnings Aug 12US Equity

$0.74▲ $0.04 (+5.62%)

Market closed · at close

1h—

24h▲ 5.6%

7d▼ 3.3%

14d▼ 17.3%

30d▼ 28.4%

1y▼ 97.4%

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $0.74 – $0.75
52-Week Range: $0.71 – $31.65
Volume: $2.54B
Avg Volume: $1.84B
Shares Outstanding: 3.5M
Next Earnings: Oct 26, 2026

Fundamentals Snapshot

Annual Revenue: $464,108
Last Q Revenue: $128,382
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-38.91
Dividend Yield: —

Why Investors Own ARTL

✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
✓Healthy economics — 25% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$464,108▲ +45.2% YoY

Gross Margin (TTM)

25.2%▲ +2.3% YoY

Operating Income (TTM)

$98,391▲ +45.2% YoY

Free Cash Flow (TTM)

$136,448▲ +45.2% YoY

About ARTELO BIOSCIENCES INC

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

🦦